HAMPTON, N.J. (PRWEB) August 11, 2020
Until recently, there were many barriers to adoption of 3D cell culture, due to a lack of tools, protocols and products for assisting with both the culturing and characterization of these models. During this time, Corning has been heavily focused on delivering tools to accelerate adoption and has commercialized many technologies and tools which now enable any researcher to easily incorporate 3D cell culture into their lab.
The Visikol® HISTO-M™ reagents will now be sold through Corning as Corning® 3D Clear Tissue Clearing Reagent and will help support the characterization of 3D cell culture models in one simple workflow, allowing for even more advancement in drug screening and other essential areas of research. This tissue clearing approach was designed specifically to be compatible with 3D cell culture models and is a simple and efficient way to enable researchers to easily generate and effectively image these models using high content imaging. The use of tissue clearing reagents allows for 3D cell culture models to be imaged in 3D with confocal microscopy, enabling the whole population of cells to be surveyed and researchers to address complex spatial questions, in addition to improving the accuracy of their assays.
“At Corning, we continue to work toward breaking down the barriers to adoption for 3D cell culture models, as they have become increasingly useful in studying critical disease areas,” said Kim Titus, Director of Business Operations, Corning Life Sciences. “By enhancing our portfolio with this new product, we aim to provide a rapid, easy-to-use process allowing researchers to add a new dimension to their research; making it easy to integrate 3D imaging into existing tissue processing workflows.”
"We developed the Visikol tissue clearing technology to enable researchers to fully characterize 3D cell culture models so that they can leverage the extensive spatial data that makes these models intrinsically more valuable than traditional 2D cell culture models," described Visikol CEO Michael Johnson, Ph.D.
Visikol is continually focused on developing imaging, digital pathology and cell culture tools and services that enable researchers to accelerate their research and to generate quantitative insights. Recently, Visikol launched several novel 3D cell culture assays which leverage its expertise in high content imaging to assess NASH and general liver toxicity.
About Visikol Incorporated
Visikol is a CRO that is focused on accelerating drug discovery and development through the use of its imaging, digital pathology and advanced cell culture assay services. The company provides end-to-end preclinical services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, multiplex imaging, high content imaging, digital pathology and custom drug discovery solutions. Visikol’s expertise is in transforming tissues and cells into large image-based data sets that can be mined for actionable insights such that pharmaceutical and biotech companies can make more quantitative and informed decision during the drug development process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit http://www.visikol.com.